Short Term Stocks To Buy Based on Stock Prediction Algorithm: Returns up to 37.04% in 3 Days

Short Term Stocks To Buy

This forecast is part of the Risk-Conscious Package, as one of I Know First’s equity research solutions to find short term stocks to buy. We determine our aggressive stock picks by screening our algorithm daily for higher volatility stocks that present greater opportunities but are also riskier. The full Risk-Conscious Package includes a daily forecast for a total of 40 stocks divided into four main categories:

  • Top 10 Aggressive stocks for the long position
  • Top 10 Aggressive stocks for the short position
  • Top 10 Conservative stocks for the long position
  • Top 10 Conservative stocks for the short position


Package Name: Risk-Conscious – Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 3 Days (05/07/2017 – 05/11/2017)
I Know First Average: 6.10%
Short Term Stocks To Buy

In this 3 Days forecast for the Risk-Conscious – Aggressive Stocks Forecast Package, there were many high performing trades and the algorithm correctly predicted 6 out 10 stocks. The top-performing prediction in this forecast was VRX, which registered a return of 37.04%. Other notable stocks were ENDP and CLMT with a return of 20.23% and 14.10%. The package had an overall average return of 6.10%, providing investors with a premium of 6.30% over the S&P 500’s return of -0.20% during the same period.

Valeant Pharmaceuticals International, Inc. (VRX) develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. (VRX) was founded in 1983 and is headquartered in Laval, Canada.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.